Cardinal Health (NYSE:CAH) Price Target Raised to $139.00 at UBS Group

Cardinal Health (NYSE:CAH) had its price objective raised by analysts at UBS Group from $134.00 to $139.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s price target indicates a potential upside of 21.30% from the company’s current price.

A number of other brokerages also recently weighed in on CAH. Argus upped their price target on shares of Cardinal Health from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Barclays upped their price target on shares of Cardinal Health from $117.00 to $133.00 and gave the stock an “overweight” rating in a report on Monday. Morgan Stanley upped their price objective on shares of Cardinal Health from $114.00 to $119.00 and gave the stock an “overweight” rating in a research report on Thursday, August 15th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Cardinal Health from $115.00 to $119.00 and gave the stock a “hold” rating in a research report on Friday, August 16th. Finally, Wells Fargo & Company upped their price objective on shares of Cardinal Health from $95.00 to $101.00 and gave the stock an “underweight” rating in a research report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $121.92.

Cardinal Health Trading Down 1.3 %

NYSE CAH traded down $1.54 during trading on Monday, reaching $114.59. The company’s stock had a trading volume of 656,268 shares, compared to its average volume of 2,066,088. The firm has a market capitalization of $27.73 billion, a price-to-earnings ratio of 33.12, a price-to-earnings-growth ratio of 1.49 and a beta of 0.60. Cardinal Health has a 12 month low of $93.17 and a 12 month high of $119.13. The firm has a 50 day moving average price of $111.75 and a 200 day moving average price of $104.17.

Cardinal Health (NYSE:CAH) last issued its quarterly earnings results on Friday, November 1st. The company reported $1.88 earnings per share for the quarter, topping analysts’ consensus estimates of $1.64 by $0.24. Cardinal Health had a net margin of 0.37% and a negative return on equity of 54.85%. The company had revenue of $52.28 billion during the quarter, compared to the consensus estimate of $50.90 billion. During the same quarter in the prior year, the firm posted $1.73 EPS. The firm’s quarterly revenue was down 4.3% on a year-over-year basis. On average, equities analysts forecast that Cardinal Health will post 7.61 EPS for the current fiscal year.

Insider Buying and Selling at Cardinal Health

In other Cardinal Health news, insider Jessica L. Mayer sold 17,896 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $106.48, for a total value of $1,905,566.08. Following the completion of the transaction, the insider now directly owns 94,529 shares in the company, valued at approximately $10,065,447.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CEO Jason M. Hollar sold 26,716 shares of the stock in a transaction on Friday, August 16th. The shares were sold at an average price of $108.87, for a total transaction of $2,908,570.92. Following the completion of the sale, the chief executive officer now directly owns 244,091 shares in the company, valued at $26,574,187.17. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jessica L. Mayer sold 17,896 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $106.48, for a total transaction of $1,905,566.08. Following the sale, the insider now owns 94,529 shares of the company’s stock, valued at approximately $10,065,447.92. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 113,963 shares of company stock worth $12,379,980. 0.09% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CAH. Point72 Asset Management L.P. bought a new position in Cardinal Health during the second quarter worth $90,440,000. Acadian Asset Management LLC lifted its stake in shares of Cardinal Health by 19.1% in the first quarter. Acadian Asset Management LLC now owns 3,723,159 shares of the company’s stock valued at $416,585,000 after buying an additional 598,002 shares in the last quarter. Jupiter Asset Management Ltd. bought a new position in shares of Cardinal Health in the first quarter valued at $56,454,000. Jacobs Levy Equity Management Inc. lifted its stake in shares of Cardinal Health by 265.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 657,526 shares of the company’s stock valued at $73,577,000 after buying an additional 477,682 shares in the last quarter. Finally, Swedbank AB bought a new position in shares of Cardinal Health in the first quarter valued at $48,673,000. 87.17% of the stock is owned by institutional investors.

Cardinal Health Company Profile

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.